Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025

Rhea-AI Summary

Heartflow (Nasdaq: HTFL) will present late-breaking clinical and economic data on its AI-driven Heartflow Plaque Analysis at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10.

The featured late-breaking presentation, “Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction,” is scheduled for Nov 9, 12:30 p.m. CST. Heartflow will present seven abstracts, including FISH&CHIPS and PRECISE trial analyses, cost-effectiveness modeling, population plaque-volume trends over seven years, and secondary analyses from REVELUTION.

Note: Heartflow Plaque Analysis is FDA-cleared; Heartflow Plaque Staging is investigational.

Insights

Cardiovascular AI Research Analyst

Late-breaking AHA presentations strengthen clinical evidence for Heartflow Plaque Analysis and highlight near-term clinical readouts on November 9, 2025.

Heartflow advances the clinical case for its AI plaque tools by presenting late-breaking outcome data and seven total abstracts at AHA, including a focused session on coronary CT plaque as a predictor of death and myocardial infarction on November 9, 2025. The material combines prognostic analysis from FISH&CHIPS and multicenter trial results, a cost-effectiveness poster, and secondary trial analyses, which together provide multiple, independently reportable metrics relevant to clinical adoption and reimbursement discussions.

The main dependencies are the actual results shown at the embargoed presentation and whether the outcomes demonstrate statistically meaningful prediction of hard endpoints; the release notes that Heartflow Plaque Staging remains investigational while the underlying Plaque Analysis device is FDA-cleared. That distinction limits immediate regulatory claims but still allows scientific validation to influence guideline committees, payers, and referral pathways if the results are robust.

Watch the live presentation on November 9, 2025 and the cost-effectiveness poster for concrete metrics such as hazard ratios, confidence intervals, and economic assumptions; these items will determine clinical and payer impact over the next 6–18 months. Expect near-term shifts in clinical discussion and payer evaluations if the outcome associations and cost models are favourable.

Data to highlight the precision of AI-powered Heartflow Plaque Staging framework in predicting long-term cardiovascular outcomes

MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic value of Heartflow Plaque Analysis at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10 in New Orleans.

The late-breaking Plaque Analysis data evaluate risk prediction with Heartflow Plaque Staging* and will remain under embargo until the featured science presentation, “Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction” on Sunday, November 9, at 12:30 p.m. CST. Timothy Fairbairn, M.D., principal investigator for the FISH&CHIPS study, Liverpool Heart and Chest Hospital NHS Foundation Trust, and Associate Professor at the University of Liverpool, will present the study.

With seven abstracts at this year’s AHA Scientific Sessions, Heartflow is significantly advancing the scientific foundation for Plaque Analysis as a key advance guiding cardiovascular risk prediction and personalized treatment. As the established leader in AI-driven coronary care, Heartflow continues to invest in high-quality research to benefit all stakeholders in the healthcare system, fully demonstrating the utility of the Heartflow One platform in transforming CAD into a manageable disease.

“Heartflow’s presentations at the AHA Scientific Sessions reflect our ongoing investment in clinical research to validate Plaque Analysis with Heartflow Plaque Staging, empowering cardiologists to personalize treatment plans using non-invasive precision technology,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer at Heartflow. “By providing AI-driven insights into plaque quantification, we’re helping clinicians see the full picture of coronary artery disease and building more effective pathways for diagnosis, management, and prevention.”

Heartflow’s data presentations at AHA will include:

Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction

• Session: Pan Vascular Interventions: Anatomy and Interventions Across Various Vascular Beds
• Presenter: Timothy Fairbairn, M.D.
• Date: Sunday, November 9
• Time: 12:30-12:38 p.m. CST
• Location: Clinical Science Zone 1‚ Moderated Digital Poster 5
  

Improvements in Diagnostic and Therapeutic Cardiovascular Risk Assessment Through Total Plaque Volume Burden: An Analysis of the FISH&CHIPS Study
Finalist for the Quest Diagnostics Early Career Investigator Award for Preventive Cardiovascular Medicine Research

• Session: Quest Diagnostics Early Career Investigator Award for Preventive Cardiovascular Medicine Research Competition
• Presenter: Shyon Parsa, M.D., Internal Medicine Resident at Stanford University Hospital
• Date: Sunday, November 9
• Time: 10:30-10:40 a.m. CST
• Location: 208-209
  

Population Changes in AI Coronary Plaque Volumes over 7 Years

• Session: New Frontiers in Cardiovascular Risk: Trends and Drivers in Cardiovascular Mortality and Outcomes
• Presenters: Allen Taylor, M.D., F.A.C.C., F.A.H.A., Chairman of Cardiology, MedStar Heart and Vascular Institute and Professor of Medicine at Georgetown University and Matthew Budoff, M.D., Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles (UCLA) Medical Center
• Date: Saturday, November 8
• Time: 10:30-11:30 a.m. CST
• Location: Population Science Zone
  

AI-enabled Plaque Phenotype Analysis of Coronary Computed Tomography Angiography Findings in Patients with Nonacute Chest Pain using FFR_CT: Results from the PRECISE Trial

• Session: Imaging Insights from Multicenter Clinical Trials
• Presenter: Jonathon Leipsic, M.D., F.R.C.P.C., M.S.C.C.T., Professor and Chair of Radiology and Professor of Cardiology at the University of British Columbia
• Date: Saturday, November 8
• Time: 11:34-11:39 a.m. CST
• Location: Clinical Science Zone 1‚ Moderated Digital Poster 8
  

Cost-Effectiveness of AI-Enabled Coronary Plaque Analysis for Management of Stable Coronary Artery Disease

• Session: Transforming Cardiac Imaging and Risk Assessment Through AI
• Presenter: Daniel D'Attilio, Director, Healthcare Economics and Outcomes Research, Heartflow
• Date: Saturday, November 8
• Time: 12:36-12:41 p.m. CST
• Location: Clinical Science Zone 1‚ Moderated Digital Poster 4
  

Statin Use Mitigates Androgen Deprivation Therapy-Associated Coronary Atherosclerosis in Prostate Cancer: A Secondary Analysis of the REVELUTION Randomized Clinical Trial

• Session: Cardiac Amyloidosis and Cardiometabolic Conundrums
• Presenter: Marly van Assen, Ph.D., Co-director of the Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Head of CT and AI Research, and Assistant Professor, Emory University
• Date: Saturday, November 8
• Time: 2:27-2:32 p.m. CST
• Location: Clinical Science Zone 2‚ Moderated Digital Poster 19
  

Accelerated Coronary Atherosclerosis Following Relugolix Versus Leuprolide Androgen Deprivation Therapy in Men with Prostate Cancer (REVELUTION): An Open-Label Randomized Controlled Trial

• Session: Where Cancer and Cardiovascular Disease Collide: Risks, Disparities, and Evolving Evidence
• Presenter: Marly van Assen, Ph.D., Co-director of the Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Head of CT and AI Research, and Assistant Professor, Emory University
• Date: Saturday, November 8
• Time: 3:15-3:20 p.m. CST
• Location: Population Science Zone‚ Moderated Digital Poster 12
  

Heartflow invites AHA attendees to a Heart Theater Symposium exploring how AI-driven plaque quantification is transforming CAD management:

AI-Plaque Analysis: The Paradigm Shift in CAD Management

• Moderator: Seth Martin, M.D., M.H.S., FAHA, Professor of Medicine and Cardiologist at Johns Hopkins School of Medicine
• Panelists: Fatima Rodriguez, M.D., F.A.C.C., Section Chief of Preventive Cardiology and Associate Professor in the Division of Cardiovascular Medicine at Stanford University, and Ron Blankstein, M.D., Director of Cardiac Computed Tomography at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School
• Date: Sunday, November 9
• Time: 3:15-4:00 p.m. CST
• Location: Heart Theater 1
  

*Heartflow Plaque Analysis is an FDA-cleared device. Heartflow Plaque Staging is an investigational-only framework and its safety and effectiveness have not been reviewed by the FDA.

About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly 500,000 patients worldwide. Key benefits include:

• Proprietary data pipeline: Built from more than 110 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001.

About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Media Contact
Elliot Levy
elevy@heartflow.com

Investor Contact
Nick Laudico
nlaudico@heartflow.com

FAQ

When will Heartflow present late-breaking plaque analysis data at AHA 2025 (HTFL)?

The late-breaking presentation is on Nov 9, 2025 at 12:30 p.m. CST during AHA Scientific Sessions 2025.

What topic will Heartflow's late-breaking AHA 2025 (HTFL) presentation cover?

The presentation is titled “Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction.”

How many Heartflow abstracts will be presented at AHA Scientific Sessions 2025 (HTFL)?

Heartflow will present seven abstracts across clinical, population, cost-effectiveness, and trial analyses.

Which trials and studies are included in Heartflow's AHA 2025 (HTFL) presentations?

Presentations include analyses from FISH&CHIPS, PRECISE, and REVELUTION, plus population and cost-effectiveness studies.

Is Heartflow Plaque Analysis FDA-cleared and what is the status of Plaque Staging (HTFL)?

Heartflow Plaque Analysis is FDA-cleared; Heartflow Plaque Staging is described as an investigational-only framework not reviewed for safety or effectiveness by the FDA.

Where and when is the Heartflow Heart Theater symposium on AI-plaque analysis (HTFL)?

The Heart Theater symposium, “AI-Plaque Analysis: The Paradigm Shift in CAD Management,” is on Nov 9, 2025, 3:15–4:00 p.m. CST at Heart Theater 1.